Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.
Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.
Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Arthroplasty Inflammation Prophylaxis With Celecoxib
- Conditions
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2007-09-21
- Lead Sponsor
- Zanbilowicz, Adam, DPM MS
- Target Recruit Count
- 200
- Registration Number
- NCT00533247
Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT00527982
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2011-06-30
- Lead Sponsor
- ARCAGY/ GINECO GROUP
- Target Recruit Count
- 157
- Registration Number
- NCT00525096
Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT00520845
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
Celecoxib for Reducing Morphine Requirement After Thyroid Surgery: A Randomized Controlled Trial
- Conditions
- Interventions
- First Posted Date
- 2007-08-24
- Last Posted Date
- 2010-11-09
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 80
- Registration Number
- NCT00520338
- Locations
- 🇹🇭
Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-08-23
- Last Posted Date
- 2012-05-18
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT00520091
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
- Conditions
- Interventions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00503035
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial
- Conditions
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2007-07-12
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 900
- Registration Number
- NCT00500279
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
🇰🇷Seuoul National University Hospital, Seoul, Korea, Republic of
Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 107
- Registration Number
- NCT00499655
- Locations
- 🇺🇸
South Pasadena Cancer Center, South Pasadena, California, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer
- Conditions
- First Posted Date
- 2007-06-14
- Last Posted Date
- 2007-06-14
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Registration Number
- NCT00486460
- Locations
- 🇮🇱
Sourasky Medical Center, Tel Aviv, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.